{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:33:00Z","timestamp":1793313180938,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117002","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:25:52Z","timestamp":1790825152000},"page":"117002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus recommendations for neurofibromatosis type 1 management in Asia Pacific"],"prefix":"10.1016","volume":"29","author":[{"given":"Yemima","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Pak-Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-6388","authenticated-orcid":false,"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3168-8209","authenticated-orcid":false,"given":"Ee Shien","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-4193","authenticated-orcid":false,"given":"Zhichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117002_bib1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2026.117002_bib2","first-page":"62","article-title":"Neurofibromatosis Type 1: Review and Update on Emerging Therapies","volume":"8","author":"Karaconji","year":"2019","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"10.1016\/j.isci.2026.117002_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117002_bib4","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.isci.2026.117002_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s13402-025-01054-9","article-title":"From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors","volume":"48","author":"Yu","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib7","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1017\/cjn.2025.10409","article-title":"A national modified Delphi consensus on the referral and management of NF1 plexiform neurofibroma","volume":"53","author":"Lafay-Cousin","year":"2025","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.isci.2026.117002_bib9","unstructured":"Real-Time Neurofibromatosis Guidelines Update 2026 - Guideline Central. https:\/\/www.guidelinecentral.com\/insights\/jan-2026-neurofibromatosis-guideline-realtime."},{"key":"10.1016\/j.isci.2026.117002_bib10","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"Akshintala","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib12","first-page":"1384","volume":"35","author":"\u2160\u578b\u795e\u7ecf\u7ea4\u7ef4\u7624\u75c5\u4e34\u5e8a\u8bca\u7597\u4e13\u5bb6\u5171\u8bc6","year":"2021","journal-title":"Chin. J. Reparative Reconstr. Surg."},{"key":"10.1016\/j.isci.2026.117002_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41431-023-01404-x","article-title":"Preimplantation genetic testing for Neurofibromatosis type 1: more than 20 years of clinical experience","volume":"31","author":"Vernimmen","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.isci.2026.117002_bib14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.isci.2026.117002_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3345\/cep.2020.00871","article-title":"Neurofibromatosis type I: points to be considered by general pediatricians","volume":"64","author":"Kang","year":"2021","journal-title":"Clin. Exp. Pediatr."},{"key":"10.1016\/j.isci.2026.117002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.isci.2026.117002_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1590\/0004-282X20150042","article-title":"Neurofibromatosis: part 2 \u2013 clinical management","volume":"73","author":"Batista","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.isci.2026.117002_bib21","article-title":"Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm","volume":"7","author":"Adeyemi","year":"2025","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.isci.2026.117002_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/msp2.70020","article-title":"Mirdametinib (Gomekli) wins FDA approval, bringing relief to NF-1 patients with surgically inoperable plexiform neurofibromatosis worldwide","volume":"2","author":"Zeb","year":"2025","journal-title":"Malignancy Spectrum"},{"key":"10.1016\/j.isci.2026.117002_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MS9.0000000000004341","article-title":"FDA approval of mirdametinib for NF1-associated plexiform neurofibromas: clinical and regulatory perspectives","volume":"88","author":"Sheikh","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.isci.2026.117002_bib24","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib25","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117002_bib26","article-title":"Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study","volume":"14","author":"Wang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.isci.2026.117002_bib27","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","article-title":"Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib28","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117002_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117002_bib30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/neuonc\/noag112","article-title":"TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"28","author":"Sadat Kiaei","year":"2026","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib46","doi-asserted-by":"crossref","first-page":"iii420","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1-associated plexiform neurofibromas: A report from PNOC and the NF Clinical Trials Consortium","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib48","first-page":"1878","article-title":"Efficacy and safety of tunlametinib in adults with inoperable neurofibromatosis type 1-associated plexiform neurofibromas: Phase IIa trial and biomarker research","volume":"32","author":"Wang","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117002_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","article-title":"MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus","volume":"24","author":"de Blank","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","article-title":"Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.isci.2026.117002_bib32","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1093\/neuonc\/noae180","article-title":"Selumetinib for plexiform neurofibroma: advances and ongoing challenges","volume":"26","author":"Wang","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/children9010038","article-title":"Malignant Peripheral Nerve Sheath Tumors\u2014A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management","volume":"9","author":"Knight","year":"2022","journal-title":"Children"},{"key":"10.1016\/j.isci.2026.117002_bib34","doi-asserted-by":"crossref","first-page":"FNL8","DOI":"10.2217\/fnl-2018-0026","article-title":"Therapeutic Targets for Malignant Peripheral nerve Sheath Tumors","volume":"14","author":"Natalie Wu","year":"2019","journal-title":"Future Neurol."},{"key":"10.1016\/j.isci.2026.117002_bib35","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1097\/JS9.0000000000001756","article-title":"Epidemiologic and survival analysis of malignant peripheral nerve sheath tumors: a retrospective cohort study","volume":"110","author":"Huang","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.isci.2026.117002_bib36","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision","volume":"37","author":"de Blank","year":"2017","journal-title":"J. Neuro Ophthalmol."},{"key":"10.1016\/j.isci.2026.117002_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.isci.2026.117002_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14791\/btrt.2022.0006","article-title":"Recent Update in Pharmacological Agents for Optic Pathway Glioma","volume":"10","author":"Park","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.isci.2026.117002_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-014-1652-6","article-title":"Single agent vinorelbine in pediatric patients with progressive optic pathway glioma","volume":"121","author":"Cappellano","year":"2015","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1215\/15228517-2006-030","article-title":"Temozolomide in children with progressive low-grade glioma","volume":"9","author":"Gururangan","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.117002_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.992673","article-title":"Novel treatments in optic pathway gliomas","volume":"2","author":"Maheshwari","year":"2022","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.isci.2026.117002_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117002_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."}],"updated-by":[{"DOI":"10.1016\/j.isci.2026.118077","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:00:00Z","timestamp":1795132800000}}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:07:11Z","timestamp":1792764431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226023801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226023801"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117002","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations for neurofibromatosis type 1 management in Asia Pacific","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117002"}}